SCHEMBL25811886

SCHEMBL25811886

Cc1[nH]c2ccc(C(=N)NCCN3CCCCC3)cc2c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.67
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPC1 O15118 1/20 0.54
GFER P55789 1/20 0.54
PARP1 P09874 2/20 0.47
ACKR3 P25106 1/20 0.46
HTR3A P46098 1/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
THRB P10828 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TLR9 Q9NR96 1/20 0.44
TLR7 Q9NYK1 1/20 0.44
ALOX15 P16050 1/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812220 0.89 ALDH1A1 (0.54) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25811307 0.86 KMT2A (0.88) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25811263 0.85 KMT2A (0.85) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25811246 0.83 KMT2A (0.82) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL30312303 0.83 KMT2A (0.82) KMT2ARAB9ASMN1; SMN2NPC1GFER
SCHEMBL25811497 0.77 KMT2A (0.73) KMT2ARAB9ASMN1; SMN2NPC1PARP1
SCHEMBL25811210 0.76 KMT2A (0.70) KMT2ASMN1; SMN2PARP1MAPTLMNA
SCHEMBL25811247 0.75 KMT2A (0.69) KMT2APARP1HTR3AMAPTKDM4E
SCHEMBL25811253 0.75 KMT2A (0.69) KMT2APARP1ACKR3HTR3AMAPT
SCHEMBL25814895 0.73 KMT2A (0.61) KMT2ARAB9ASMN1; SMN2NPC1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 KMT2A 981/4885RAB9A 729/4885SMN1; SMN2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.